One of the main achievements in the field of radiation oncology for breast cancer has been preservation of the breast using breast conservation therapy (BCT), classically defined as local excision of the primary tumor to achieve negative margins followed by whole breast (WB) radiation therapy (RT). Historically, all patients with early-stage breast cancer (eBC) were treated with some form of mastectomy, requiring en bloc removal of the breast, the underlying musculature, and axillary lymph nodes. Multiple prospective, randomized studies have now demonstrated that BCT has equivalent long-term outcomes to mastectomy for eBC. [1] [2] [3] Furthermore, the Early Breast Cancer Trialists Collaborative Group meta-analysis of the randomized studies, with over 7,300 patients, has demonstrated not only a significant decrease in ipsilateral breast tumor recurrence (IBTR) with the use of radiation, but also that radiation therapy can influence survival, changing the paradigm that radiation affects local control only. 4 This meta-analysis has conclusively shown that adjuvant
Current Status
Most of the existing published data on APBI come from retrospective, single-institution, or single-arm prospective series. While there are three published randomized prospective studies comparing APBI with cfWBRT, only one of these trials showed equivalent local control with the use of APBI (see the section on interstitial brachytherapy techniques below). [18] [19] [20] Notably, the patients treated in this study were highly selected, low-risk patients. The other two studies both reported increased IBTR for the patients treated with APBI. Although the existing data are deficient in terms of randomized study design and long-term follow-up regarding efficacy and toxicity, the available clinical data collectively suggest that APBI may be a safe and effective therapy in appropriately selected patients.
There are several techniques for delivering APBI, including interstitial brachytherapy, single-lumen or multiple-lumen balloon brachytherapy, phase III trial is an ongoing prospective, randomized study comparing APBI with cfWBRT, and has been one of the fastest accruing trials for breast cancer owing to its appeal to both physicians and patients.
Patients are randomized to cfWBRT versus APBI, with the caveat that the choice of APBI technique (i.e. interstitial, lumen-based, or externalbeam-based) is left to the discretion of the treating physician. While mature results are not expected for many more years, APBI is being increasingly used in large academic centers, small community-based hospitals, and private practice settings, both on and off protocol.
Breast Cancer 21 The proposed criteria classify patients into one of three groups: suitable, cautionary, or unsuitable (see Table 1 ). The suitable group, based on data from phase II studies supporting the use of APBI, includes low-risk patients for whom WBRT would be unlikely to confer a survival benefit. The cautionary and unsuitable groups represent patients for whom minimal data exist supporting APBI and in whom cfWBRT has a proven survival benefit.
Accelerated Partial Breast Irradiation Techniques Interstitial Brachytherapy
The earliest APBI technique utilized interstitial brachytherapy catheters.
This technique therefore has the longest average published patient follow-up (5.4 years) and the most patient-years of follow-up. 21 
struts (see Figure 1) , thus allowing for multiple source-placement options to avoid high doses to the skin and chest wall. 27 Early clinical experience suggests that excellent dosimetry is achievable, even for patients who would have otherwise been ineligible for other brachytherapy owing to the proximity of the cavity to the skin or chest wall. 28 The second device, the Contura (SenoRx, Inc., Irvine, CA), consists of a central catheter lumen plus four additional surrounding lumens, each containing multiple dwell positions. Similar to SAVI, early data suggest that the Contura device allows for adequate coverage of the treatment volume while limiting doses to the skin and chest wall. [29] [30] [31] [32] There is also now a multilumen MammoSite balloon brachytherapy applicator with four lumens to allow for dose optimization.
3D Conformal Radiation Therapy
More recently, 3D-CRT has been used to target the lumpectomy cavity plus margin using external-beam radiation therapy (EBRT) delivered with a conventional linear accelerator (see Figure 2) . The advantages of this technique include the non-invasive delivery method, the widespread availability of linear accelerators compared with brachytherapy methods, and the familiarity of EBRT delivery techniques for all practicing radiation oncologists. One disadvantage of 3D-CRT is the multiple-beam configuration, which causes a significant distribution of low-dose radiation over a much larger volume, including the lungs, the ribs, and the contralateral breast owing to the multiple, often co-planar, beams that are required to converge in the high-dose region of the target volume; this has raised concerns regarding increased long-term toxicity. Furthermore, a larger margin around the tumor bed is required to take into account patient motion/set-up errors.
Interestingly, the majority of patients in RTOG 0413 were treated with 3D-CRT, despite the fact that this technique has the least amount of clinical data on efficacy and toxicity and the shortest follow-up compared with the other APBI techniques. Thus, the RTOG 0413/NSABP B-39 trial will provide important information regarding 3D-CRT; while we await mature data from this important trial, 3D-CRT APBI should be utilized on-protocol only.
RTOG 0319 was a prospective, single-arm phase II trial designed to assess the reproducibility and technical feasibility of using 3D CRT, with secondary end-points of efficacy and toxicity, with the anticipation of being able to allow the technique to be used in RTOG 0413. This trial utilized 38.5Gy in 10 fractions delivered twice daily (biologically equivalent to 34Gy for brachytherapy). Initial efficacy results at a median follow-up of 4.5 years for 52 evaluable patients revealed an IBTR rate of 6% and an ipsilateral nodal failure rate of 2%, with 4% grade III toxicities. 33 It is unclear how the toxicity and cosmetic outcome of 3D-CRT compares with that of WBI or other APBI techniques. Wernicke et al.
reported the preliminary results of a prospective single-institution study using 'mini-tangents' in a prone position to deliver 30Gy in five fractions over 10 days. Ninety-two percent of patients reported good to excellent cosmesis at 28-month follow-up. 34 By contrast, Jagsi et al. delivered
IMRT with deep-inspiration breath-hold to 34 patients in a prospective study in which 38.5Gy in 10 fractions twice daily was used. They reported early closure of the trial at a median of 2.5 years owing to the high incidence (>20%) of compromised cosmesis with the use of breath-holding. 35 Additional concerning toxicity data using 3D-CRT APBI come from the Tufts group, where 64 patients were treated according to the 3D-CRT technique specified in RTOG 0413. After a median follow-up of only 15 months, grade 3-4 toxicity was noted in 8.3% of patients, and 18.4% of patients reported either 'fair' (11.7%) or 'poor' (6.7%) cosmetic outcome.
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Intraoperative Radiotherapy Breast Cancer IORT patients received additional EBRT after APBI owing to adverse pathologic features, these results are encouraging in that IORT was comparable to cfWBRT in selected patients.
Hypofractionated Whole Breast Irradiation

Rationale for Fractionated Radiotherapy
The rationale for using conventional fractionation (small daily fractions to a high total dose) is based on theoretic radiobiologic modeling of the relative sensitivity to changes in the dose of normal cells to that of cancer cells. Typically, most tumor types have relatively low sensitivity to changes in fraction size, whereas normal, late-reacting tissue has higher sensitivity. Since theoretically the goal of radiation is to maximize the tumor cell kill while minimizing the cell kill of normal tissue, the rationale for using low doses of conventional fractionation (1.8-2.0Gy, see Figure 3A ) was to limit the damage to normal late-reacting tissue while maximizing cell kill for tumor cells. While the exact sensitivity of breast tumor cells was not known until recently, it was presumed that breast tumors, like most other tumors, have low sensitivity compared with late-reacting tissue.
Accelerated Partial Breast Irradiation and Hypofractionated Whole Breast Radiation
Recently, in a landmark trial of hypofractionated radiation therapy for breast cancer, a radiobiologic surrogate for sensitivity (termed α/β ratio) was calculated for breast tumors based on coefficients estimated from the Cox multivariate model. Surprisingly, the surrogate was found to be similar to the normal, late-reacting breast tissue, 39 suggesting that breast tumors and normal tissue have similar sensitivity to dose fraction size. Therefore, there may be little or even no therapeutic advantage of using a smaller fraction size for breast cancer to reduce cell kill in normal tissue relative to tumor cells (see Figure 3B ).
Clinical Data for Hypofractionated Whole Breast Radiation Therapy
With the support of radiobiologic models and the increased demand for shorter radiotherapy regimens, several preliminary reports using daily fractions of 2.5-2.7Gy over approximately three weeks have demonstrated low rates of local recurrence and acceptable toxicity. [40] [41] [42] Based on these experiences, larger randomized phase III trials were initiated comparing hWBRT versus cfWBRT.
The strongest phase III data supporting the use of hWBRT randomized patients to 50Gy in 25 fractions versus 42.5Gy in 16 fractions for nodenegative tumors measuring <5cm (no DCIS) after breast-conserving surgery. With a median follow-up of 12 years, there was no observed difference between the groups in the risk for IBTR or cosmetic outcome.
Of note, this trial did not allow boost irradiation, which has since become routinely used for eBC. 43 hWBRT has not yet been studied in a prospective fashion for DCIS, although limited retrospective data suggest that hWBRT may be safely used for in situ disease. were not statistically different for the three arms. Patients who received 41.6Gy had similar rates of late adverse effects to the control group, whereas the 39Gy cohort had slightly fewer late sequelae based on photographic and patient self-assessment. 39 In the START-B trial, the randomization was 40Gy in 15 fractions versus 50Gy in 25 fractions, with more than 40% of women receiving a 10Gy boost to the tumor bed. After a median follow-up of six years, there was no significant difference in IBTR (2.2 and 3.3%, respectively). Again, a slightly lower rate of late adverse effects was noted in the hypofractionated group. 45 Given the theoretically increased risk for late effects with larger fraction sizes, long-term follow-up of more than 10-15 years will be required to ensure the safety of these particular regimens.
Based on the early success of the hypofractionated regimens outlined above, the START investigators have initiated the FAST trial, which will randomize women to conventional fractionation, 30Gy in five fractions, or 28.5Gy in five fractions, given once per week using 3D-CRT or IMRT.
A variety of other hWBRT techniques and fractionation schedules are being explored ,41,46-49 such as concurrent boost treatment (where the boost dose is delivered at the same time as the WBRT, thus shortening the overall duration of treatment) and combinations of IORT followed by a hypofractionated external-beam course post-operatively. 50, 51 Recently, a task force authorized by ASTRO performed a systematic literature review of available data regarding hypofractionated radiation for breast cancer and have generated a consensus statement. The panel concluded that for patients with early-stage breast cancer meeting the criteria specified in Table 2 , the data support the use of hWBRT. There were several patient groups for whom no consensus was reached, due to lack of sufficient data (i.e. patients < 50 years of age, receipt of chemotherapy, and >7% dose heterogeneity in the breast).
No consensus was reached regarding the use of a boost in conjunction with hWBRT, since boost was not routinely delivered in the vast majority of patients treated in these trials. Lastly, the task force recommended that the heart be excluded from the primary treatment fields when hypofractionation is used.
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Conclusions
The benefits of cfWBRT as a component of BCT for eBC are well documented and include substantially improved local control, a modest survival benefit, and minimal toxicity. APBI and hWBRT are under intense investigation as possible alternatives to cfWBRT that would allow for expedited completion of radiotherapy. There are maturing phase III data suggesting that hWBRT is a safe and effective alternative to cfWBRT for eBC. While preliminary data suggest that APBI is feasible and safe for appropriately selected, low-risk patients, results from randomized phase III trials are eagerly awaited. Until mature data are available to support APBI, providers should approach its implementation cautiously. n Breast Cancer 
